Pharmaceutical composition, pharmaceutical preparation and application

Through the components such as astragalus membranacetin, styrene glycoside, peony glycoside and other components in the pharmaceutical composition, combined with the PI3K/Akt signaling pathway, the treatment problems of blood deficiency syndrome and renal inflammatory reaction are solved, and the hematopoietic function and kidney health are significantly improved, thus achieving Effective treatment of blood deficiency syndrome and renal inflammation response.

CN118903173APending Publication Date: 2024-11-08TSING HUA DE REN XIAN HAPPINESS PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411130434.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat blood deficiency syndrome and its renal inflammatory response caused by it, and the prevalence of anemia is increasing year by year, especially in children and developing countries.

Method used

Using a pharmaceutical composition, including astragaloside, styrene glycoside, peonylin, nothocytolactone, privetin, isoflavones, molten pigment and syringo acid, through network pharmacology and molecular docking technology , the PI3K/Akt signaling pathway combined with these components regulates hematopoietic factor levels and inhibits renal inflammatory response.

Benefits of technology

This pharmaceutical composition can restore the pathological morphology of the kidney, improve hematopoietic function, activate the PI3K/Akt signaling pathway, regulate the level of hematopoietic factors, significantly improve blood deficiency syndrome and renal inflammatory response, and protect renal function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903173A_ABST
    Figure CN118903173A_ABST
Patent Text Reader

Abstract

The invention provides a pharmaceutical composition, which is prepared from the following raw materials in parts by weight: 10 to 18 parts of astragaloside, 140 to 220 parts of stilbene glucoside, 220 to 350 parts of paeoniflorin, 7 to 15 parts of demethylwedelolactone, 13 to 20 parts of specnuezhenide, 140 to 220 parts of isoflavone, 46 to 70 parts of morin and 100 to 180 parts of pidoxyloside acid. The pharmaceutical composition disclosed by the invention has a treatment effect on blood deficiency rats, and can be used for inhibiting kidney inflammatory response, protecting basic functions of kidneys, activating PI3K / Akt signal channels and regulating the level of hematopoietic factors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and in particular relates to a pharmaceutical composition, a pharmaceutical preparation containing the pharmaceutical composition, and application thereof Background Art

[0002] According to traditional Chinese medicine, the pathogenesis of blood deficiency syndrome is caused by excessive blood loss and insufficient hematopoiesis. Clinical manifestations include pale face, dizziness, pale lips, general weakness and mental weakness. Due to the damage of the body's hematopoietic function, it often leads to pancytopenia, decreased visceral function, decreased immunity, and even bone marrow suppression in severe cases. Modern medicine believes that anemia patients are often accompanied by symptoms of blood deficiency, which are common in renal anemia, iron deficiency anemia, aplastic anemia and anemia after radiotherapy and chemotherapy. Due to factors such as the aging of the population, dietary habits, drug treatment and the fast-paced modern lifestyle, the prevalence of anemia has increased year by year and tends to be younger. Data show that up to 80% of patients suffer from anemia every year, among which the incidence of anemia in developing countries is much higher than that in developed countries; according to a survey by the Chinese Center for Disease Control and Prevention, the anemia rate of children in my country is about 25%. For this reason, the study of blood deficiency syndrome has attracted more and more attention and has become a hot spot in current drug research and development.

[0003] Nephritis is a group of immune-mediated kidney diseases involving inflammatory mediators such as complement, cytokines, reactive oxygen species, etc. It ultimately leads to inflammatory changes in the intrinsic tissues of the kidney and causes varying degrees of renal dysfunction, which can be caused by a variety of reasons. The present invention uses network pharmacology methods to analyze and study, screens out active pharmaceutical ingredients that have significant therapeutic effects on blood deficiency syndrome and kidney inflammation, and analyzes and verifies through animal experiments, screens out a pharmaceutical composition that can synergistically exert its efficacy, and can simultaneously treat or improve blood deficiency syndrome and kidney inflammation caused by blood deficiency. Summary of the invention

[0004] In view of the problems existing in the prior art, the present invention provides a pharmaceutical composition, a pharmaceutical preparation comprising the pharmaceutical composition, and the pharmaceutical composition, and the use of the pharmaceutical preparation comprising the pharmaceutical composition in the preparation of a drug for treating blood deficiency syndrome or inhibiting kidney inflammatory response.

[0005] The objective of the present invention is achieved through the following technical solutions: The first aspect of the present invention provides a pharmaceutical composition, which consists, by weight, of 10-18 parts of astragaloside IV, 140-220 parts of diphenylethylene glycosides, 220-350 parts of paeoniflorin, 7-15 parts of norwedelic acid, 13-20 parts of terunculoside, 140-220 parts of isoflavones, 46-70 parts of morin and 100-180 parts of dogwood acid.

[0006] Preferably, in parts by weight, the pharmaceutical composition consists of 10-16 parts of astragaloside IV, 140-200 parts of distilbene glycosides, 220-320 parts of paeoniflorin, 7-10 parts of demethylwedelactone, 13-18 parts of terunculoside, 140-200 parts of isoflavones, 46-65 parts of morin and 100-140 parts of dogwood acid.

[0007] Preferably, in parts by weight, the pharmaceutical composition consists of 10 parts of astragaloside IV, 140 parts of diphenylethylene glycosides, 220 parts of paeoniflorin, 7 parts of norwedeholactone, 13 parts of terunculoside, 140 parts of isoflavones, 46 parts of morin and 100 parts of pteridophytic acid.

[0008] Preferably, in parts by weight, the pharmaceutical composition consists of 16 parts of astragaloside IV, 200 parts of diphenylethylene glycosides, 320 parts of paeoniflorin, 10 parts of norwedeholactone, 18 parts of terunculoside, 200 parts of isoflavones, 65 parts of morin and 140 parts of dogwood acid.

[0009] Preferably, in parts by weight, the pharmaceutical composition consists of 18 parts of astragaloside IV, 220 parts of distilbene glycosides, 350 parts of paeoniflorin, 15 parts of norwedeholactone, 20 parts of terunculoside, 220 parts of isoflavones, 70 parts of morin and 180 parts of dogwood acid.

[0010] In a second aspect, the present invention provides a pharmaceutical preparation, which comprises the above-mentioned pharmaceutical composition.

[0011] Preferably, the pharmaceutical preparation is a solid preparation, a semisolid preparation or a liquid preparation.

[0012] Preferably, the solid preparation includes powder, tablet, capsule, disintegrant, granule and / or pill; the semisolid preparation includes gel and / or paste; the liquid preparation includes emulsion, mixture, suspension, syrup, oral solution and / or injection.

[0013] The third aspect of the present invention provides use of the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in the preparation of a drug for treating blood deficiency syndrome.

[0014] The fourth aspect of the present invention provides the use of the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in the preparation of a drug for inhibiting kidney inflammatory response.

[0015] Compared with the prior art, the beneficial effects of the present invention are: In the present invention, astragaloside and isoflavones are both main components of Astragalus, and astragaloside has a significant effect on anemia after chemotherapy; diphenylethylene glycoside is a main component of Polygonum multiflorum, and diphenylethylene glycoside can increase the number of WBC after chemotherapy and improve bone marrow hematopoietic function; terepril glycoside is a main component of Ligustrum lucidum, and studies have reported that it can treat bone marrow suppression caused by CTX and regulate the expression of hematopoietic factors in the body. Morin is a natural bioflavonoid, which is widely present in different species of Moraceae. According to some experiments, it can regulate the PI3K / Akt / mTOR signaling pathway, improve the antioxidant level, reverse cell apoptosis, autophagy, etc., and prove that morin can produce a chemoprotective effect on acute neurotoxicity induced by the chemotherapy drug ifosfamide by intervening in inflammatory and apoptosis markers, such as NF-κB and B-celllymphoma-2 (Bcl-2). Paeoniflorin, a water-soluble monoterpene glycoside, is the main bioactive component of white peony. Studies have shown that paeoniflorin has a wide range of in vitro and in vivo pharmacological effects, and can significantly increase the number of peripheral blood WBC, CFU-GM, CFU-E and CFU-M in radiation-induced BDS mice. Cibotium barometz is an effective component of Cibotium barometz, which can not only enhance the liver and kidney functions of the body, but also play a role in postpartum hemostasis, anti-inflammatory and antiviral effects.

[0016] The present invention uses network pharmacology and molecular docking technology to dock key targets such as PI3K, AKT1, IL-6, etc. with the above 7 components. The docking results show that PI3K and AKT1 have good binding scores with the above 7 components.

[0017] Through animal experiments, it was found that the pharmaceutical composition of the present invention can restore kidney pathological morphology; it can increase the PI3K / Akt phosphorylation level (P<0.05), increase the expression of Bcl-2 (P<0.05), increase the expression of EPO and EPOR (P<0.05), and reduce the TNF-u content (P<0.05); it can increase the expression of EPO (P<0.05), reduce the expression of TNF-u (P<0.05), and the SXBM and FEJ groups can simultaneously increase the levels of serum hematopoietic factors IL-6 and IL-1β (P<0.05).

[0018] In summary, the pharmaceutical composition of the present invention has a therapeutic effect on blood deficiency rats, and can inhibit kidney inflammatory response, protect basic kidney functions, activate PI3K / Akt signaling pathway, and regulate the level of hematopoietic factors. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 PPI network diagram of shared targets (A) Shared target network diagram of Shengxuebao mixture in the treatment of BDS (B) Top 20 key targets; Figure 2 This is the Shengxuebao mixture-ingredients-targets-disease network diagram; Figure 3 This is a GO functional enrichment analysis diagram; Figure 4 This is the KEGG pathway analysis diagram; Figure 5 shows the 3D and 2D images of the molecular docking results; Figure 6 shows the HE staining results of kidney tissues of rats in each group, and the black arrows indicate glomeruli; Figure 7 is the expression of EPO and TNF-α in the serum of rats in each group; Figure 8 shows the effect of Shengxuebao mixture on IL-6 and IL-1β in the serum of BDS rats; Fig. 9 To investigate the effect of Shengxuebao mixture on key signaling pathway proteins in rat kidney. DETAILED DESCRIPTION

[0020] The technical solutions and beneficial effects of the present invention will be further described below through specific embodiments. Example 1

[0021] The present embodiment provides a pharmaceutical composition, which consists, in parts by weight, of 10 parts of astragaloside IV, 140 parts of distilbene glycosides, 220 parts of paeoniflorin, 7 parts of norwedeholactone, 13 parts of terunculoside, 140 parts of isoflavones, 46 parts of morin and 100 parts of dogwood acid. Example 2

[0022] The present embodiment provides a pharmaceutical composition, which consists of 16 parts of astragaloside Ⅳ, 200 parts of diphenylethylene glycosides, 320 parts of paeoniflorin, 10 parts of norwedeholactone, 18 parts of terunculoside, 200 parts of isoflavones, 65 parts of morin and 140 parts of dogwood acid, in parts by weight. Example 3

[0023] The present embodiment provides a pharmaceutical composition, which consists of 18 parts of astragaloside IV, 220 parts of distilbene glycosides, 350 parts of paeoniflorin, 15 parts of norwedeholactone, 20 parts of teruncosides, 220 parts of isoflavones, 70 parts of morin and 180 parts of dogwood acid, in parts by weight. Example 4

[0024] This embodiment provides a pharmaceutical preparation, comprising the pharmaceutical composition described in embodiment 2. The pharmaceutical preparation is a mixture, and in some other preferred embodiments, the pharmaceutical preparation is a powder, tablet, capsule, disintegrant, granule, pill, gel, paste, emulsion, suspension, syrup, oral solution or injection.

[0025] 1. Materials 1.1 Database and software Function database Website Compound and target disease target protein name conversion TCMSPTCMIDGenecardsUniprot https: / / old.tcmsp-e.com / tcmsp.php https: / / bidd.group / TCMID / https: / / www.genecards.org / https: / / www.uniprot.org / Common target analysis Protein interaction network analysis Venny2.1.0 STRING https: / / bioinfogp.cnb.csic.es / tools / venny / https: / / cn.string-db.org / GO and KEGG analysis DAVID6.8 https: / / david.ncifcrf.gov / Draw a bubble chart ImageGP http: / / www.ehbio.com / ImageGP / index.php / home / in dex / upsetview.html Network construction and analysis Molecular simulation and docking Cytoscape3.7.2DiscoveryStudio2020 https: / / cytoscape.org / Installation Package 1.2 Experimental instruments instrument factory model ELISA reader Rayto RT-6100 Shaker Servicebio TSY-B Electrophoresis Apparatus Shanghai Tianneng Technology Co., Ltd. G0002 Vortex mixer USA / Scilogex MX-S Chemiluminescence imaging system Nikon Japan Nikon DS-U3 Scanner EPSON V370 Grayscale analysis software AlphaInnitech alphaEaseFC Desktop high speed refrigerated centrifuge DRAGONLAB D3024R Chemiluminescence analyzer CLINX 6300 Paper Cutter Deli No.8014 Ice Maker SIMAG SPR80 1.3 Experimental reagents and consumables Reagents factory Part Number EPO Antibody Proteintech Biotechnology Co., Ltd. 66975-1-Ig EPOR antibodies SABSignalwayAntibody #38497-1 PI3K Antibodies Affinity Biotechnology Centre Ltd AF6241 P-PI3K Antibody Affinity Biotechnology Centre Ltd AF3241 AKT Antibody Proteintech Biotechnology Co., Ltd. 60203-2-Ig P-AKT Antibody Affinity Biotechnology Centre Ltd 66444-1-Ig TNF-α Antibody Abcam Ab205587 Bcl-2 Antibody Abcam ab194583 β-actin Abcam Ab8226 Rat EPO ELISA Kit Nanjing Jiancheng Bioengineering Research Institute Co., Ltd. HO51 Rat IL-6 ELISA Kit Shenzhen Xinbosheng Biological Co., Ltd. ERC003 Rat Il-1β ELISA Kit Shenzhen Xinbosheng Biological Co., Ltd. ERC007 RIPA Lysis Buffer Beyotime P0013C 5× Protein Loading Buffer MCMBiotech WB2001 Protein molecular weight markers Proteintech PL00001 Twain 20 Solarbio TB220 ECL Proteintech PK1003 Goat anti-rabbit Abcam Ab150077 Goat anti-mouse Abcam Ab6789 Electrophoresis fluid Servicebio G2018-1L Transfer solution Servicebio G2019-1L Blood-producing mixture Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. 220823 Acetylphenylhydrazine Sinopharm Chemical Reagent Co., Ltd. A100226 Cyclophosphamide Jiangsu Hengrui Medicine Co., Ltd. 20221129 Compound donkey-hide gelatin paste Shandong Dong'e Ejiao Co., Ltd. 2211047 4% paraformaldehyde Servicebio G1101-500ML Anhydrous ethanol Sinopharm Chemical Reagent Co., Ltd. 100092693 Sodium Pentobarbital Merck 57-33-0 0.9% Sodium Chloride Shandong Chenxin Pharmaceutical Co., Ltd. E23021322 Astragaloside IV Munster (Chengdu) Biotechnology Co., Ltd. A0070 Stilbene Glycol Sichuan Jingcuibao Biotechnology Co., Ltd. JCBE018 Paeoniflorin Sichuan Jingcuibao Biotechnology Co., Ltd. JCBS010 Wedelolide Sichuan Jingcuibao Biotechnology Co., Ltd. JCBY036 Ligustrum lucidum Sichuan Jingcuibao Biotechnology Co., Ltd. JCBT005 Isoflavones Maclean S834647 Morin Sichuan Jingcuibao Biotechnology Co., Ltd. JCBS049 Pteridophytic acid Snort Biology SNT187 2. Methods

[0026] Network pharmacology and molecular docking technology play an important role in the field of traditional Chinese medicine compound. It can visualize the analysis of traditional Chinese medicine compound, find the main components, key targets and pathways from the database, explore the mechanism of traditional Chinese medicine compound in an integrated and coherent manner, and finally verify it in vitro and in vivo experiments. The authenticity and scientificity of computer simulation are guaranteed.

[0027] TCMSP and TCMID databases were selected as websites for searching information on Chinese herbal medicine components and structures. Based on OB (oral bioavailability) and DL (drug similarity), OB ≥ 30% and DL ≥ 0.18 were determined as the key ingredient screening conditions. Shengxuebao mixture contains 7 Chinese herbs. "Prepared Polygonum multiflorum", "Astragalus", "White Peony", "Eclipta prostrata", "Ligustrum lucidum", "Mulberry", and "Ciphala cibotii" were set as keywords to collect chemical components on the TCMSP and TCMID platforms.

[0028] In order to standardize the names of protein targets, the protein targets corresponding to the active ingredients screened from the TCMSP database were entered into the Uniprot database at one time, the species was limited to "Homosapiens", and the format was converted to "Genesymbol" to obtain the protein target information corresponding to the ingredient.

[0029] The GeneCards database was searched using the keyword "Blood deficiency syndrome" and the species selected was "Homo Sapiens". The collected targets were saved in an EXCEL table.

[0030] After deleting duplicates from all ingredient targets in the Shengxuebao mixture, enter the Venny website, with ingredient targets as List1 and disease targets as List2. The intersection of the two is the common target of the drug and the disease.

[0031] The common targets of drugs and diseases were analyzed through the STRING database, and "HomoSapiens" was selected with a confidence level of 0.900 (Highestconfidence>0.9) to draw a PPI network diagram. The network visualization software Cytoscape was then used for data analysis and processing, and NetworkAnalyzer was selected to analyze the network topology characteristic values ​​such as degree centrality (Degree) and combined score (combinedscore).

[0032] To explore the biological process, molecular function, cellular components and related pathways of Shengxuebao mixture in the treatment of BDS. The enriched results were obtained through the DAVID database, and the results ranked in the top 20 by Count (number of genes) were selected, and the bubble chart was drawn using the ImageGP online tool. Finally, the "drug-ingredient-disease-target" network diagram was constructed in the Cytoscape software and analyzed with "NetworkAnalyzer".

[0033] The molecular structures of active compounds and protein structures of overlapping targets were downloaded from the compound database and PD website, respectively. Virtual docking of compounds and targets was performed using the DS20 program and visualized using PyMOL software. The specific analysis is as follows: First, the ligands of active compounds in Shengxuebao mixture were collected (MOL2 format) and the ligands were processed. Second, the water molecules in the original ligands and protein receptors were removed, saved in PDB format, and then converted to PDBQT format. Finally, molecular docking was performed: AutoGrid was used to set the lattice size and parameters. After the docking was completed, the binding energy was used as a reference to screen out molecules with stronger binding ability in Shengxuebao mixture. The binding energy ≤-5.0kJ / mol was used as a standard to evaluate the good binding ability of molecules with targets.

[0034] Male Sprague Dawley rats were purchased from the Experimental Animal Center of the Air Force Medical University. The standard license number for experimental animals is IACUC-20231256. The body weight is (250±20) g. The temperature and humidity during the feeding process are 22±2℃ and 50-70%, respectively. The rats are then allowed to adapt to the environment and fed for seven days before the next experiment. All animals and operations comply with the relevant regulations on experimental animal ethics and are approved by the Air Force Medical University Experimental Animal Ethics Review. The clinical medication of Shengxuebao mixture stipulates that the dosage is 15ml / time, three times a day. According to the body surface area of ​​rats and humans, the rat dosage is 5.25ml / kg. The medium-dose group of Shengxuebao mixture is set at 2.62ml / kg, and the low-dose group is set at 1.31ml / kg. The experimental animals were divided into six groups according to the random number table method: blank group (Control), model group (Model group), Fufangejiaojiang group (FEJ) 6ml / kg, high dose (Shengxuebao mixture high dose, Shengxuebao mixture-H) 5.24ml / kg, medium dose group (Shengxuebao mixture middle dose, Shengxuebao mixture-M) 2.62ml / kg and low dose group (Shengxuebao mixture low dose, Shengxuebao mixture-L) 1.31ml / kg. The BDS model was established by subcutaneous injection of APH and intraperitoneal injection of CTX. The specific method was as follows: on the basis of the blank control group, the Model group, Shengxuebao mixture group and FEJ group were subcutaneously injected with APH 20mg·kg-1 on the first day, subcutaneously injected with APH 40mg·kg-1 on the fourth day, and intraperitoneally injected with CTX 25mg·kg-1 2h later. The model can be replicated by continuous injection for 4 days. The blank control group was injected with an equal volume of normal saline. The mice were gavaged from the first day and the drug was administered for a total of 10 days.

[0035] Kidney tissue was fixed with 4% paraformaldehyde, then trimmed, dehydrated, embedded, sliced, stained, and sealed. Tissue sections were observed in detail at different magnifications to detect basic pathological changes in the sections, such as congestion, necrosis, and inflammatory changes. The sections were analyzed under a light microscope and photographed with an objective lens.

[0036] (1) Embedding and sectioning: The fixed kidney slices were transferred to a dehydration box and dehydrated with 75%, 85%, 90%, 95% and 100% alcohol at different time sequences; the tissues were then immersed in xylene solution, the wax-impregnated tissues were placed in an embedding machine and cut into parallel straight lines using a small paraffin cutter.

[0037] (2) Hematoxylin-eosin staining: After hematoxylin staining for 30 minutes, rinse with running water for 1 minute, then decolorize with 1% hydrochloric acid-alcohol for 2 seconds, restain with ammonia water for 1 minute, and finally stain with eosin for 20 to 40 seconds.

[0038] (3) Dehydration and sealing: Dehydrate the slices in different concentrations of ethanol, then air dry and seal with neutral gum. Avoid bubbles during the entire operation.

[0039] (4) Photographing and analyzing results: Observe and collect images using a microscope for result analysis.

[0040] According to the instructions of the kit, enzyme-linked immunosorbent assay (ELISA) was used to detect EPO and TNF-u, IL-6 and IL-1β in rat serum.

[0041] 1) Protein extraction: Weigh 20 mg of kidney tissue on an analytical balance, place in a 1.5 mL centrifuge tube and place on ice, prepare RIPA lysis buffer and protein phosphatase inhibitor in a ratio of 100:1, add 300 uL of the prepared lysis buffer to each sample and grind. After grinding, place on ice for lysis for 30 min, then centrifuge at 12,000 rpm for 30 min in a 4°C centrifuge, and collect the supernatant in a new EP tube for later use.

[0042] 2) Protein quantification: Prepare the BCA quantification kit and configure the standard and AB working solution according to its instructions. First add the prepared concentration gradient standard to the 96-well plate, then add 2uL of sample, and then immediately add 200uL of working solution, incubate at 37° for 30min, measure the absorbance at 576nm and draw a standard curve. After calculating the protein concentration, add 5X protein loading buffer to each group and shake and mix, boil the protein for 10min, and place it in a -20° refrigerator after it returns to room temperature.

[0043] 3) Glue preparation: After cleaning and draining the device used for gel preparation, add double distilled water to check for leaks for 10 minutes. At the same time, prepare the separation gel and concentrated gel. First add the separation gel and let it solidify, then add the concentrated gel 40 minutes later. Immediately insert the comb vertically, and wait for 30 minutes for solidification before adding the sample.

[0044] 4) Electrophoresis and transfer: Prepare samples and protein markers, add samples and perform electrophoresis under the parameters of S1 (80V, 30min) and S2 (120V, 1.5h). After electrophoresis, soak the PVDF membrane in methanol for 30s, introduce transfer solution and transfer device, lay layers into a sandwich structure, and transfer under the conditions of (100V, 1h).

[0045] 5) Sealing and primary antibody incubation: Prepare 5% skim milk. After the membrane is transferred, take out the PVDF membrane in the clip and put it into skim milk. Slowly shake it on a shaker for 1 hour and then seal it. After sealing, wash it with PBST three times, 10 minutes each time, and incubate it with the prepared primary antibody dilutions EPO (1:1000), EPOR (1:1000), PI3K (1:500), p-PI3K (1:500), Akt (1:800), p-AKT (1:800), TNF-α (1:700), Bcl-2 (1:1000). After sealing, wash it with PBST three times, 10 minutes each time, and then incubate it with the prepared primary antibody dilutions at 4° for 8 hours.

[0046] 6) Incubation with secondary antibody: Place the primary antibody at room temperature for 30 minutes, rinse with PBST three times, 10 minutes each time, incubate with the corresponding type of antibody at room temperature for 1 hour, and then rinse with PBST three times, 10 minutes each time.

[0047] 7) Luminescence and grayscale analysis: Prepare AB luminescent liquid with a ratio of A:B=1:1, apply the luminescent liquid on the surface of the strip, and detect it through an imaging system and computer software ImageLab. After the detection, use ImageJ software for grayscale analysis.

[0048] 2.3 Statistical analysis All data were expressed as mean ± standard deviation (X ± SD) and analyzed using the statistical software Graphpad Prism 8.0. One-way ANOVA was used to analyze the significant differences among the groups. P <0.05 indicates that the results are statistically significant. P <0.01 indicated significant differences.

[0049] 3. Results 3.1 Network pharmacology results

[0050] The components after searching and screening in the TCMSP database are shown in Table 1. A total of 62 components were collected after screening.

[0051] Table 3-1 Chemical components screened from Shengxuebao mixture MolID MoleculeName Oral bioavailability OB (%) Drug-like DL MOL010300 dIDP(6Z,10E,14E,18E)-2,6,10,15,19,23- 41.08 0.57 MOL002372 hexamethyltetracosa-2,6,10,14,18,22-hexaene 33.55 0.42 MOL006209 Cyanin 47.42 0.76 MOL000737 Morin 46.23 0.27 MOL002773 beta-carotene 37.18 0.58 MOL000098 Quercetin 46.43 0.28 MOL000358 beta-sitosterol 36.91 0.75 MOL000422 Kaempferol 41.88 0.24 MOL004576 Taxifolin 57.84 0.27 MOL005146 LucidumosideD 48.87 0.71 MOL005147 LucidumosideD_qt 54.41 0.47 MOL005169 (20S)-24-ene-3β,20-diol-3-acetate 40.23 0.82 MOL005190 Eriodictyol 71.79 0.24 MOL005195 syringaresinoldiglucoside_qt 83.12 0.80 MOL005209 Lucidusculine 30.11 0.75 MOL005211 Olitoriside 65.45 0.23 MOL005212 Olitoriside_qt 103.23 0.78 MOL000006 Luteolin 36.16 0.25 MOL000098 Quercetin 46.43 0.28 MOL001790 Listen 39.84 0.71 MOL001689 Acacetin 34.97 0.24 MOL002975 Butin 69.94 0.21 MOL003378 1,3,8,9-tetrahydroxybenzofuran[3,2-c]chromen-6-one 33.94 0.43 MOL003389 3'-O-Methylorobol 57.41 0.27 MOL003398 Pratensein 39.06 0.28 MOL003402 Demethylwedelolactone 72.13 0.43 MOL003404 Wedelolactone 49.6 0.48 MOL000006 Luteolin 36.16 0.25 MOL000098 Quercetin11alpha,12alpha-epoxy-3beta-23- 46.43 0.28 MOL001910 dihydroxy-30-norolean-20-en-28,12beta-olide 64.77 0.38 MOL001918 Paeoniflorgenone (3S,5R,8R,9R,10S,14S)-3,17-dihydroxy-4,4,8,10,14- 87.59 0.37 MOL001919 pentamethyl-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-15,16-dione 43.56 0.53 MOL001921 Lactiflorin 49.12 0.80 MOL001924 Paeoniflorin 53.87 0.79 MOL001925 paeoniflorin_qt 68.18 0.40 MOL001928 albiflorin_qt 66.64 0.33 MOL001930 benzoylpaeoniflorine 31.27 0.75 MOL000211 Mairin 55.38 0.78 MOL000358 beta-sitosterol 36.91 0.75 MOL000359 Sitosterol 36.91 0.75 MOL000422 Kaemppherol 41.88 0.24 MOL000492 (+)-catechin 54.83 0.24 MOL000211 Mairin 55.38 0.78 MOL000239 Jaranol 50.83 0.29 MOL000296 Hederagenin(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl- 36.91 0.75 MOL000033 17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol 36.23 0.78 MOL000354 isorhamnetin 49.6 0.31 MOL000371 3,9-di-O-methylnissolin 53.74 0.48 MOL000374 5'-hydroxyiso-muronulatol-2',5'-di-O-glucoside 41.72 0.69 MOL000378 7-O-methylisomucronulatol 74.69 0.30 MOL000379 9,10-dimethoxypterocarpan-3-O-β-D-glucoside 36.74 0.92 MOL000380 dihydro-6H-benzofurano[3,2-c]chromen-3-ol 64.26 0.42 MOL000387 Bifendate 31.1 0.67 MOL000392 formononetin 69.67 0.21 MOL000398 isoflavanone 109.99 0.3 MOL000417 Calycosin 47.75 0.24 MOL000422 kaempferol 41.88 0.24 MOL000433 FA 68.96 0.71 MOL000098 Quercetin 46.43 0.28 MOL000438 (3R)-3-(2-hydroxy-3,4-dimethoxyphenyl)chroman-7-ol 67.67 0.26 MOL000439 isomucronulatol-7,2'-di-O-glucosiole 49.28 0.62 MOL000442 1,7-Dihydroxy-3,9-dimethoxypterocarpene 39.05 0.48

[0052] The targets corresponding to the active ingredients of Shengxuebao mixture were deduplicated and imported into the Uniprot database to convert gene names, resulting in a total of 324 targets. 615 anemia disease targets with a score greater than 15 were screened out using the Genecards database, and 66 potential targets of Shengxuebao mixture for the treatment of BDS were obtained by taking the intersection in Venny.

[0053] The common targets of drug components and diseases that were screened were imported into the STRING database, and a network model of protein-protein interaction and PPI enrichment was established. The degree centrality and comprehensive score of the network topology feature values ​​were analyzed using NetworkAnalyzer. The results showed that the main targets were TNF, IL-6, AKT1, etc. Figure 1 .

[0054] The common targets of Shengxuebao mixture and seven medicinal materials-compound components-BDS diseases were summarized into a table and imported into Cytoscape3.7.2 software to construct a drug-compound-disease common target network diagram. Figure 2 .

[0055] The DAVID online analysis tool was used to perform GO enrichment analysis on the common target proteins of Shengxuebao mixture components and BDS, including biological processes, molecular functions and cellular components. The results showed that the main biological processes regulated by Shengxuebao mixture in BDS included negative regulation of RNA polymerase II promoter transcription, apoptosis process, drug response, immune response, etc. Figure 3 The DAVID online analysis tool was used to perform KEGG enrichment analysis on Shengxuebao mixture. The results showed that the mechanism of Shengxuebao mixture regulating BDS was mainly related to PI3K / Akt, HIF-1 and other signaling pathways. The KEGG bubble diagram of the top 20 pathways was drawn by sorting by P<0.01 value, see Figure 4 .

[0056] Nine compounds with high ranking in the "active compound-target-pathway" network, including astragaloside IV, stilbene glycoside, peony glycoside, demethylwedeholic acid, terunciolidine, isoflavones, and dog spine pteridinic acid, were selected for molecular simulation docking with the main target genes IL-6, TNF-α, and AKT1. The lower the binding energy, the more stable the conformation. Binding energy <-7.0 kcal / mol indicates that the molecule has a strong binding ability and a certain stability with the target. Ki (inhibition rate constant) is less than 10 μmol / L, which is a molecule with good inhibitory activity against the target. The docking results in Table 2-2 show that PI3K has a good binding score with peony glycoside (-7.2), AKT1 has a good binding score with demethylwedeholic acid (-7.3), IL6, TNF-α, and IL-1β have a good binding with stilbene glycoside (-5.2), isoflavones (-5.8), and astragaloside IV (-6.1), respectively. The results showed that the eight active ingredients had good binding activity and stability with the five core targets, showing good affinity. Figure 5 .

[0057] Table 3-2 Molecular docking results Target Stilbene Glycol Paeoniflorin Astragaloside IV Ligustrum lucidum Morin Wedelolide Dogwood fern Isoflavones PI3K -6.5 -7.2 -8.4 -8.1 -8.2 -6.5 -8 -7.4 AKT1 -9.2 -9.2 -10.2 -7.9 -9.9 -7.3 -8.7 -4.4 IL-6 -5.2 -5.3 -4.7 -4.2 -4.4 -4.9 -3.8 -5.1 TNF-α -8.7 -10.9 -7.6 -8.9 -1 -7.5 -8.4 -5.8 IL-1β -4.7 -5.5 -6.1 -5.1 -5 -5.2 -8.1 -4.7

[0058] Take 0.16g of astragaloside IV, 2g of distilbene glycoside, 3.2g of paeoniflorin, 0.1g of norwedelic acid, 0.18g of teruncoside, 2g of isoflavones, 0.65g of morin and 1.4g of dogwood acid, mix, dissolve in ethanol, concentrate under reduced pressure, and freeze-dry to obtain a sample.

[0059] Fifty rats were randomly divided into five groups, with 10 rats in each group. The rats were weighed, recorded and marked.

[0060] The animals were grouped as follows: (1) Normal group: administered with normal saline.

[0061] (2) Model group: administered with normal saline.

[0062] (3) Sample low-dose group: Dosage: 0.035 g kg-1, dissolved in physiological saline.

[0063] (4) Sample medium dose group: Dosage: 0.087 g kg-1, dissolved in physiological saline.

[0064] (5) Sample high-dose group: Dosage: 0.140 g kg-1, dissolved in physiological saline.

[0065] Administration method: Rats were given intragastric administration for 10 consecutive days.

[0066] HE staining was used to observe the pathological state of kidney tissue in BDS rats. Figure 6 As shown, compared with the C group, the glomeruli of the rats in the M group were reduced, a small amount of cell necrosis appeared in the renal tissue, the number of RBCs in the renal interstitial capillaries decreased, and the glomerular capsule cavity and renal tubular lumen expanded. Compared with the rats in the M group, the expansion of the glomerular capsule cavity and renal tubular lumen in the sample group and the FEJ group was significantly reduced, the density of necrotic cells decreased, and the content of RBCs in the interstitial capillaries increased. The staining showed that the pharmaceutical composition and pharmaceutical preparation of the present invention can have a restorative effect on the renal damage caused by BDS rats.

[0067] Since blood deficiency syndrome can cause varying degrees of damage to the kidneys and bone marrow, the kidney's ability to synthesize EPO is reduced, and the secretion of hematopoietic factors is disordered, resulting in a decrease in the body's hematopoietic ability. In mammals, EPO produced by the kidneys is essential for the production of RBCs. After adulthood, the kidneys become the main site of EPO production, and TNF-α, as an important inflammatory factor and negative hematopoietic factor, is essential for hematopoiesis. Figure 7As shown in the data, serum EPO and TNF-α were detected by ELISA. Compared with group C, the EPO level in group M was significantly decreased (P<0.05), and the expression of TNF-α was significantly increased (P<0.05). Both the sample group and the FEJ group could up-regulate EPO (P<0.05) and down-regulate TNF-α (P<0.05), indicating that the sample group can promote the secretion and synthesis of renal EPO, reduce renal inflammatory response, and have a good improvement on renal function.

[0068] The connection between hematopoietic function and bone marrow hematopoiesis was described earlier. Maintaining the balance of hematopoietic factors plays an important role in restoring the body's hematopoietic function. IL-6 and IL-1β are important positive regulatory factors for hematopoiesis. By detecting these two indicators, it can be indirectly reflected whether the treatment of BDS rats with Shengxuebao mixture is related to the regulation of hematopoietic factors in the body. IL-6 is a cytokine secreted by bone marrow stromal cells, which has multiple functions such as regulating immune response, acute phase response and hematopoiesis. IL-1β is a subtype of IL-1, which can promote the proliferation of hematopoietic stem cells (HSC) and induce other cells to produce hematopoietic factors to promote hematopoiesis. Figure 8 As shown, the ELISA method was used to detect IL-6 and IL-1β in the serum of each group of rats. It was found that compared with the C group, the IL-6 and IL-1β in the M group were significantly downregulated (P<0.05), and the IL-6 and IL-1β in the sample administration groups and the FEJ group were upregulated (P<0.05). This result suggests that the sample can improve the level of hematopoietic factors in BDS rats, thereby regulating the hematopoietic function in the body and playing a blood-enriching role.

[0069] According to the previous network pharmacology analysis results, the PI3K / Akt signaling pathway is also predicted as one of the ways to treat BDS, among which TNF-α, AKT1, etc. are predicted as important targets for the treatment of BDS. In order to verify the prediction, the expression of important targets and related targets on the PI3K / Akt signaling pathway was studied. EPO, as an important hematopoietic factor in the body, can stimulate hematopoiesis with EPOR to treat anemia. At the same time, EPO also has non-hematopoietic functions such as anti-inflammatory and anti-apoptosis. Bcl-2 is an important anti-apoptotic gene. Western blot results are as follows: Fig. 9 As shown, compared with group C, EPO and EPOR decreased in group M ( P <0.05), the phosphorylation levels of p-PI3K and p-Akt decreased ( P <0.05), Bcl-2 expression decreased ( P <0.05), TNF-α expression increased ( P<0.05). After the sample and FEJ administration, the expression of EPO and EPOR proteins was significantly increased, the phosphorylation level of PI3K / Akt was increased, TNF-α was inhibited, and Bcl-2 expression was promoted. According to the above results, EPO, phosphorylated PI3K, phosphorylated AKT, and Bcl-2 in the sample group and FEJ group were significantly increased, indicating that each therapeutic drug not only restored the expression of EPO in the kidney, but also activated the PI3K / AKT pathway, increased the Bcl-2 content, and played an anti-apoptotic and anti-inflammatory role in kidney tissue. In short, the improvement of blood deficiency symptoms by the sample is related to the activation of the PI3K / Akt pathway by EPO, the upregulation of the Bcl-2 level, and the anti-apoptotic and anti-inflammatory effects on kidney tissue.

[0070] 4. Discussion Through network pharmacology, it was found that the active ingredients in the samples, such as astragaloside IV, stilbene glycoside, peony glycoside, demethylwedelolactone, terebinthrin, isoflavones, morin, and dog spine acid, had many targets and significant pharmacological effects. Astragaloside and isoflavones are both main components of Astragalus, and astragaloside has a significant effect on anemia after chemotherapy; stilbene glycoside is the main component of Polygonum multiflorum, and stilbene glycoside can increase the number of WBC after chemotherapy and improve bone marrow hematopoietic function; terebinthrin is the main component of Ligustrum lucidum, and studies have reported that it can treat bone marrow suppression caused by CTX and regulate the expression of hematopoietic factors in the body. Morin is a natural bioflavonoid widely found in different species of Moraceae. Some experiments have shown that it can regulate the PI3K / Akt / mTOR signaling pathway, improve antioxidant levels, reverse cell apoptosis and autophagy, etc., proving that morin can have a chemoprotective effect on acute neurotoxicity induced by the chemotherapy drug ifosfamide by intervening in inflammatory and apoptotic markers such as NF-κB and B-cell lymphoma-2 (Bcl-2). Paeoniflorin, a water-soluble monoterpene glycoside, is the main bioactive component of white peony. Studies have shown that peoniflorin has a wide range of in vitro and in vivo pharmacological effects and can significantly increase the number of peripheral blood WBC, CFU-GM, CFU-E and CFU-M in radiation-induced BDS mice. Dog spine fern is an effective ingredient in dog spine, which can not only enhance the liver and kidney function of the body, but also play a role in postpartum hemostasis, anti-inflammatory and antiviral effects. Based on this, the present invention uses network pharmacology and molecular docking technology to dock key targets such as PI3K, AKT1, IL-6, etc. with the above 7 components. The docking results show that PI3K and AKT1 have good binding scores with the above 7 components. Through animal experiments, it was found that the pharmaceutical composition of the present invention can restore kidney pathological morphology; it can increase the phosphorylation level of PI3K / Akt (P<0.05), increase the expression of Bcl-2 (P<0.05), increase the expression of EPO and EPOR (P<0.05), and reduce the content of TNF-u (P<0.05); it can increase the expression of EPO (P<0.05), reduce the expression of TNF-u (P<0.05), and the SXBM and FEJ groups can simultaneously increase the content of serum hematopoietic factors IL-6 and IL-1β (P<0.05).

[0071] In summary, the pharmaceutical composition or pharmaceutical preparation of the present invention has a therapeutic effect on blood deficiency rats, and can inhibit kidney inflammatory response, protect basic kidney function, activate PI3K / Akt signaling pathway, and regulate the level of hematopoietic factors.

[0072] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition, characterized in that In terms of weight, the pharmaceutical composition consists of 10-18 parts of astragaloside IV, 140-220 parts of diphenylethylene glycosides, 220-350 parts of paeoniflorin, 7-15 parts of norwedelic acid, 13-20 parts of terunculoside, 140-220 parts of isoflavones, 46-70 parts of morin and 100-180 parts of dogwood acid.

2. The pharmaceutical composition according to claim 1, characterized in that In terms of weight, the pharmaceutical composition consists of 16 parts of astragaloside IV, 200 parts of diphenylethylene glycosides, 320 parts of paeoniflorin, 10 parts of norwedelic acid, 18 parts of terunculoside, 200 parts of isoflavones, 65 parts of morin and 140 parts of dogwood acid.

3. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the pharmaceutical composition according to any one of claims 1 to 3.

4. The pharmaceutical preparation according to claim 3, characterized in that The pharmaceutical preparation is a solid preparation, a semisolid preparation or a liquid preparation.

5. The pharmaceutical preparation according to claim 4, characterized in that: The solid preparations include powders, tablets, capsules, disintegrants, granules and / or pills; the semisolid preparations include gels and / or pastes; the liquid preparations include emulsions, mixtures, suspensions, syrups, oral solutions and / or injections.

6. Use of the pharmaceutical composition according to any one of claims 1 to 2 or the pharmaceutical preparation according to any one of claims 3 to 5 in the preparation of a drug for treating blood deficiency syndrome.

7. Use of the pharmaceutical composition according to any one of claims 1 to 2 or the pharmaceutical preparation according to any one of claims 3 to 5 in the preparation of a drug for inhibiting renal inflammatory response.